Nuo Therapeutics (AURX) CEO/CFO Jorden Emerson Acquires 8,773 Shares

What Happened
Jorden David Emerson (CEO/CFO and Director) reported two acquisitions coded as "A" (grant, award or other acquisition). On 2026-08-27 he acquired 789 shares at $1.07 each (value $844). On 2026-08-28 he acquired 7,984 shares reported at a weighted average price of $1.09 (value $8,695). Combined, Emerson acquired 8,773 shares for approximately $9,539. These filings reflect acquisitions (not sales).

Key Details

• Transaction dates: 2026-08-27 (789 shares @ $1.07, $844) and 2026-08-28 (7,984 shares @ weighted avg $1.09, $8,695).
• Total shares acquired: 8,773; total reported value: about $9,539.
• Filing: Form 4 filed 2026-08-28 (period of report 2026-08-27); filing appears timely.
• Shares owned after the transactions: not provided in the data you supplied.
• Footnote (F1): The $1.09 price for the 7,984-share line is a weighted average; those shares were purchased in multiple transactions at prices ranging $1.08–$1.10. The reporting person offers to provide per-transaction details on request.

Context

• Transaction code "A" covers grants/awards or other acquisitions; here the filing indicates these were acquisitions and the footnote clarifies that at least the larger lot was purchased in multiple trades.
• The total dollar amount is modest (~$9.5k) compared with many insider trades; purchases by executives can be of interest to investors but do not by themselves prove future performance.